Oncology Data Advisor® · Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Medical Oncologist at the National Cancer Center Hospital East in Japan, discusses his two abstracts investigating the efficacy of zolbetuximab in gastric cancers.  

Oncology Data Advisor holds the utmost value for patient advocates and advocacy groups as they strive to prioritize patient-centered care and shared decision making throughout the cancer journey. At this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor spoke with numerous individuals representing diverse asp...

Oncology Data Advisor® · Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Kathleen Moore, MD, Associate Director of Clinical R...

Oncology Data Advisor® · Accelerated Brain Age in Survivors of Childhood Cancer With Nicholas Phillips, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Nicholas Phillips, a Physician Scientist at St. Jude Children's Research Hospital, discusses his research investigating accelerated brain age and associated neurocognitive impairments experienced by childhood cancer survivors.  

Oncology Data Advisor® · Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Thomas Hutson, Director of the Urologic Oncology Cancer Research and Treatment Center at Baylor Sammons Cancer Center, discusses the resul...

Oncology Data Advisor® · Reducing Drug Waste Through Dose Rounding of Bevacizumab With Puneeth Indurlal, MD In this interview from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, Dr. Puneeth Indurlal, Senior Director for Care Transformation at the US Oncology Network, discusses his team's abstract regarding dose rounding of bevacizumab, the potential for minimizing drug waste, and reducing the cost of care.  

Oncology Data Advisor® · Impact of Social Determinants of Health on TNBC Treatment With Nicholas Robert, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor speaks with Dr. Nicholas Robert, Chief Medical Officer for Ontada, about his team's abstract regarding the impacts of social determinants of health on genetic testing and treatment selection in triple-negative breast cancer (TNBC).  

Oncology Data Advisor® · Supporting Patients Through Employment Disruptions During Cancer With Michael Halpern, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Michael Halpern, Medical Officer in the National Cancer Institute's Healthcare Delivery Research Program, discusses his team's study investigating the effects of employment disruptions on financial hardship experienced by patients with cancer. Dr. Halpern shares advice for how employers can provide support and accommodation in the workplace for their employees during cancer treatment, as well as advice for clinicians on how to partner with patients to address financial hardships.  

Oncology Data Advisor® · Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Noelle Cloven, a Gynecologic Oncologist at the Sarah Cannon Research Institute at Texas Oncology, sat down with Oncology Data Advisor to furthe...

Oncology Data Advisor® · Improving Outcomes for IDH1/2-Mutant Glioma in the INDIGO Study With Timothy Cloughesy, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Timothy Cloughesy, Director of the Neuro-Oncology Program at the University of California Los Angeles (UCLA), sat down to further discuss his presen...

Oncology Data Advisor® · mCSPC: Real World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding ...

Oncology Data Advisor® · Leveraging Community-Academic Partnerships for Latinx AYA Cancer Survivors With Stephanie Smith, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephanie Smith, Pediatric Oncologist at Stanford Medicine, sat down with Oncology Data Advisor to discuss her research on leveraging community-academic partnerships to improve access to survivorship care for Latinx adolescent/young adult (AYA) cancer survivors. Dr. Smith explains the barriers faced by this population and the unique role that community cancer centers play in providing equitable care as patients transition into adult survivorship.  

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics and treatment by disease volume among patients with metastatic castration-sensitive prostate cancer. Dr. Freedland shares more regarding the complexities of treatment decisions in prostate cancer, barriers to care, and the research that he and his team are conducting to optimize treatment utilization based on disease characteristics.  

Oncology Data Advisor® · Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Richard Newcomb, Hematology/Oncology Fellow at Dana-Farber/Mass General Cancer Center, sat down with Oncology Data Advisor to elaborate on his study regarding uncertainty and coping experienced by patients with newly diagnosed indolent non-Hodgkin lymphoma (NHL), as well as strategies for supporting patients facing distress around their diagnosis.  

Oncology Data Advisor® · Payment Reform Through the Enhancing Oncology Model With Lalan Wilfong, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Dr. Lalan Wilfong, the Senior Vice President of Payer and Care Transformation for the US Oncology ...

Oncology Data Advisor® · Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Janet Espirito, PharmD, a Senior Medical Director at Ontada, sat down with Oncology Data Advisor to discuss her presentation on identifying real-world end points for assessing response in patients receiving novel therapies for metastatic non–small cell lung cancer (NSCLC) outside of clinical trials.  

Oncology Data Advisor® · Coaching Cancer Survivors Through Digital Health: Robin Lally, PhD, and Marilyn Hammer, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Robin Lally, PhD, and Marilyn Hammer, PhD, co–Principal Investigators of the COAC...

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Robin Lally, PhD, and Marilyn Hammer, PhD, co–Principal Investigators of the COACH (Comprehensive Outcomes for After-Cancer Health) study. Dr. Lally and Dr. Hammer share the background of this study and how it is seeking to improve the cancer survivorship experience through digital health interventions and patient-reported outcomes.  

Oncology Data Advisor® · Understanding Sexual Orientation and Gender Identity Data Collection: Mandi Pratt-Chapman, PhD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Mandi Pratt-Chapman, Associate Center Director for Community Outreach, Engagement, and Equity at George Washington University Cancer Center, sat down with Oncology Data Advisor to discuss her abstract on difference-making conditions associated with sexual orientation and gender identity (SOGI) data collection among ASCO members' institutions. Dr. Pratt-Chapman gives additional insight into the importance of SOGI data collection for providing patient-centered care and shares advice for instituting data collection processes in order to help guide clinical decision making for LGBTQIA+ patients.  

Oncology Data Advisor® · Molecular Analyses of Sacituzumab Govitecan in Urothelial Carcinoma With Manoj Bupathi, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Manojkumar Bupathi, MD, MS, a Genitourinary (GU) Medical Oncologist at Sarah Cannon Research Institute and Rocky M...